A randomised phase II/III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer.
The aim of this trial is to investigate whether pre-operative treatment with chemotherapy plus radiation therapy has a better outcome than chemotherapy alone in patients undergoing surgery for resectable gastric cancer.
Primary Sponsor
Australasian Gastro-Intestinal Trials Group (AGITG)
Collaborating Groups
TROG Cancer Research; Canadian Cancer Trial Group (CCTG); European Organisation for Research & Treatment of Cancer (EORTC); National Health and Medical Research Council Clinical Trials Centre (NHMRC CTC)
Accrual Target
570
Expected Date of Accrual
31 December 2020
Trial Chairperson
Professor Trevor Leong, Peter MacCallum Cancer Centre, VIC
Trial Contact
topgear@ctc.usyd.edu.au
Related Post
18 September, 2024
TOPGEAR trial findings published in NEJM
18 September 2024: We’re thrilled to announce the release
11 September, 2024
Putting radiation medicine research on the world stage: 2024 ASM a resounding success
11 September 2024: Our 2024 Annual Scientific Meeting was
